Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Gilead Sciences, seeing a 22% boost, benefited from regulatory wins in treatments for liver disease and HIV. The company’s ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences, Inc. (NASDAQ:GILD ... quarter of commercial and operational execution with robust year-over-year revenue performance across HIV, Oncology, and Liver Disease, including 9% growth in ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...